Search

everythinglearnresearchcommunity

for

Search:↓

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

Clascoterone 5% solution is not yet commercially available, with only the 1% solution currently sold for acne. Users discuss the potential of Clascoterone as a hair loss treatment, comparing it to other anti-androgens like RU58841 and Eucapil.

A 29-year-old man regained his hairline using a consistent routine of topical minoxidil and finasteride, along with pumpkin seed oil, despite experiencing side effects like low libido and ED. He emphasizes the importance of consistency and is satisfied with his progress, choosing to avoid oral treatments due to potential side effects.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

The user is seeking advice on preserving hair follicles at Norwood stage 6 or 7 while waiting for new treatments. They are considering using treatments like Minoxidil, finasteride, or RU58841.

A new hair loss treatment claims a 539% improvement over placebo, but skepticism remains due to lack of substantial evidence and reliance on percentage figures. Users discuss the effectiveness of existing treatments like Minoxidil and Finasteride, expressing doubt about the new solution's impact.

The user experienced increased shedding and side effects like oily skin and acne after switching from finasteride to dutasteride, despite initially having success with finasteride. They also tried oral spironolactone, which reduced libido but didn't help with hair loss, and are considering returning to finasteride only.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.

Clascoterone is being discussed as a promising new hair loss treatment, showing significant improvement in trials. Despite this, skepticism persists about its effectiveness, cost, and side effects, with some users preferring minoxidil and finasteride.

The user experiences severe anxiety and physical symptoms after taking finasteride and is seeking alternative hair loss treatments since dutasteride is unavailable. They suspect an allergic reaction to finasteride and have stopped using it.

The user tried a product labeled as PP405 from Umbrella Labs for hair loss but saw no changes, and it was revealed to be a fake or misidentified product. The user is also using finasteride, minoxidil, and other treatments but is still experiencing hairline issues.

Finasteride is preferred for its shorter half-life and FDA approval, while dutasteride is seen as more effective but not FDA-approved for hair loss. Many combine these with minoxidil for improved results, though side effects and effectiveness vary.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

The user has been on dutasteride and oral minoxidil for a year with no progress and is considering increasing the dutasteride dose or adding RU58841. Other users suggest consulting a doctor, trying derma needling with topical minoxidil, and note that hair loss treatments can have varying effectiveness.

A dermatologist refused to prescribe finasteride due to concerns about recent research linking it to male breast cancer, suggesting a topical alternative with minoxidil instead. The user is advised to seek a second opinion, as the evidence for such risks is inconclusive and the dermatologist's reasoning seems questionable.

A 23-year-old male shared his 5.5-month progress using 5% topical minoxidil foam for hair regrowth, considering adding finasteride despite concerns about side effects. Users advised starting finasteride to maintain gains, with some suggesting topical options to minimize side effects.

The user is considering switching from finasteride to dutasteride for hair loss treatment and is unsure when to stop finasteride. Dutasteride takes about 15 days to reach significant DHT suppression compared to finasteride.

An 18-year-old male has been taking oral finasteride 0.25 mg daily for almost four months to address hairline recession, experiencing mild sexual side effects like softer erections and lower libido. He also uses Tugain 5%, ketoconazole, and vitamins, noticing slowed shedding but no major regrowth, and seeks advice on managing side effects and hair loss.

Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.

Dutasteride is often more effective than finasteride for hair regrowth, though it may cause initial shedding. Many users see positive results after several months, with some combining it with minoxidil for better outcomes.

Male pattern baldness is linked to health risks and should be treated medically. Finasteride is effective and should be insurance-covered.

Alcohol-free minoxidil options in Europe, particularly from a German pharmacy, are recommended for those with seborrheic dermatitis. Users suggest alternatives like Alopexy and Doppelherz foam, and emphasize avoiding propylene glycol and alcohol to reduce irritation.

Minoxidil can effectively promote hair regrowth with consistent use, but results differ among individuals. Some recommend combining it with finasteride for better long-term results, though OP chooses to use only minoxidil and accepts the possibility of going bald.

A 17-year-old is using Finasteride and Minoxidil for hair loss, experiencing hair shedding and cystic acne. They are considering Dutasteride for acne but are concerned about potential side effects on genital development.

Minoxidil and finasteride have not improved the user's hairline after a year. Suggestions include trying dutasteride, microneedling, or considering a hair transplant for better results.

The user is concerned about hair loss and is hesitant to use treatments like finasteride and minoxidil due to potential side effects. Another user suggests gradually introducing finasteride to minimize side effects and maximize results.

Finasteride is prescribed at 1mg because it is FDA-approved and proven effective, despite evidence that 0.2mg may similarly reduce DHT. The 1mg dose is more effective for hair growth, and lower doses are less available.